베타 차단제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 유형별, 적응증별, 약제별, 유통 채널별, 용도별, 지역별, 경쟁별 세분화(2020-2030년)
Beta blockers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Indication, By Drugs, By Distribution Channel, By Application, By Region and Competition, 2020-2030F
상품코드:1886323
리서치사:TechSci Research
발행일:2025년 12월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 베타 차단제 시장은 2024년에 99억 4,000만 달러로 평가되며, 2030년까지 CAGR 5.95%로 성장하며, 140억 6,000만 달러에 달할 것으로 예측됩니다. 베타 차단제는 에피네프린(아드레날린이라고도 함)이 심장과 혈관에 미치는 작용을 억제하는 작용을 하는 약물의 일종입니다. 이 작용으로 심박수가 감소하고 심 수축력이 감소하여 혈압이 낮아지고 혈류가 촉진됩니다. 베타 차단제 세계 시장은 고혈압, 협심증, 부정맥 등 심혈관계 질환의 유병률 증가와 함께 이러한 질환에 취약한 고령 인구 증가가 주요 촉진요인으로 작용하고 있습니다.
시장 개요
예측 기간
2026-2030
시장 규모 : 2024년
99억 4,000만 달러
시장 규모 : 2030년
140억 6,000만 달러
CAGR : 2025-2030년
5.95%
가장 빠르게 성장하는 부문
협심증
최대 시장
북미
주요 시장 성장 촉진요인
심혈관 질환 증가는 세계 베타 차단제 시장의 기본적인 촉진요인입니다. 고혈압, 협심증, 다양한 부정맥을 포함한 이러한 질환은 증상을 관리하고 질환의 진행을 예방하기 위한 치료적 개입이 필요합니다.
주요 시장 과제
주요 브랜드명 베타 차단제의 특허만료에 따른 영향은 세계 시장 성장에 중대한 도전이 되고 있습니다. 특허의 독점권이 상실되면 제네릭 업체들이 생물학적 동등성을 가진 제품을 출시하고 가격 경쟁이 치열해져 시장 포화가 진행됩니다.
주요 시장 동향
세계 베타 차단제 시장은 보다 진보된 약물전달 시스템 및 치료 프로파일의 지속적인 개발로 인해 큰 영향을 받고 있습니다. 이러한 추세는 신규 제제와 차세대 약물을 모두 포괄하며, 최적화된 약동학 및 부작용 감소를 통해 환자의 치료 결과를 개선하는 것을 목표로 하고 있습니다.
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 베타 차단제 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
유형별(비선택성 약제, 선택성 약제)
적응증별(협심증, 심부전, 고혈압, 기타)
약제별(Betaxolol, Acebutolol, Esmolol, 기타)
유통 채널별(병원 약국, 소매 약국, 온라인 약국)
용도별(심장질환, 고혈압, 녹내장, 기타)
지역별
기업별(2024)
시장 맵
제6장 북미의베타 차단제 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의베타 차단제 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의베타 차단제 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의베타 차단제 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의베타 차단제 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
촉진요인
과제
제12장 시장 동향과 발전
합병·인수
제품 출시
최근 동향
제13장 세계의 베타 차단제 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Pfizer Inc
Novartis AG
Merck & Co. Inc
AstraZeneca PLC
Johnson and Johnson Services, Inc.
Eli Lilly and Company
Sanofi SA
Bristol-Myers Squibb
Bayer AG
GlaxoSmithKline plc
제16장 전략적 제안
제17장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
The Global Beta blockers Market, valued at USD 9.94 Billion in 2024, is projected to experience a CAGR of 5.95% to reach USD 14.06 Billion by 2030. Beta blockers represent a class of pharmaceutical agents that function by inhibiting the effects of epinephrine, also known as adrenaline, on the heart and blood vessels. This action results in a reduced heart rate and decreased force of cardiac contraction, thereby lowering blood pressure and enhancing blood flow. The global market for beta blockers is primarily driven by the rising prevalence of cardiovascular diseases, including hypertension, angina, and arrhythmias, coupled with an expanding geriatric population that is inherently more susceptible to such conditions.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 9.94 Billion
Market Size 2030
USD 14.06 Billion
CAGR 2025-2030
5.95%
Fastest Growing Segment
Angina Pectoris
Largest Market
North America
Key Market Drivers
The increasing burden of cardiovascular diseases represents a fundamental driver for the global beta blockers market. These conditions, encompassing hypertension, angina, and various arrhythmias, necessitate therapeutic interventions to manage symptoms and prevent disease progression. The continued rise in these diagnoses directly expands the patient pool requiring cardiac medications.
Key Market Challenges
The impact of patent expirations on key brand-name beta blockers poses a significant challenge to the growth of the global market. Upon the loss of patent exclusivity, generic manufacturers introduce bioequivalent versions, intensifying price competition and increasing market saturation. This dynamic typically results in a substantial decline in revenue for originator companies as market share shifts towards these lower-priced generic alternatives.
Key Market Trends
The global beta blockers market is significantly influenced by the continuous development of more sophisticated drug delivery systems and enhanced therapeutic profiles. This trend, encompassing both novel formulations and next-generation agents, aims to improve patient outcomes through optimized pharmacokinetics and reduced side effects. For instance, the United States Pharmacopeia announced on August 30, 2024, that four new dissolution tests were added to the Metoprolol Succinate Extended-Release Tablets monograph, reflecting ongoing FDA approvals of diverse extended-release formulations.
Key Market Players
Pfizer Inc
Novartis AG
Merck & Co. Inc
AstraZeneca PLC
Johnson and Johnson Services, Inc.
Eli Lilly and Company
Sanofi SA
Bristol-Myers Squibb
Bayer AG
GlaxoSmithKline plc
Report Scope:
In this report, the Global Beta blockers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Beta blockers Market, By Type:
Non-selective Agents
Selective Agents
Beta blockers Market, By Indications:
Angina Pectoris
Heart Failure
High Blood Pressure
Others
Beta blockers Market, By Drugs:
Betaxolol
Acebutolol
Esmolol
Others
Beta blockers Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Beta blockers Market, By Application:
Cardiac Diseases
Hypertension
Glaucoma
Others
Beta blockers Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Beta blockers Market.
Available Customizations:
Global Beta blockers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Beta blockers Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Non-selective Agents, Selective Agents)
5.2.2. By Indications (Angina Pectoris, Heart Failure, High Blood Pressure, Others)
5.2.3. By Drugs (Betaxolol, Acebutolol, Esmolol, Others)
5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
5.2.5. By Application (Cardiac Diseases, Hypertension, Glaucoma, Others)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. North America Beta blockers Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Indications
6.2.3. By Drugs
6.2.4. By Distribution Channel
6.2.5. By Application
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Beta blockers Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Indications
6.3.1.2.3. By Drugs
6.3.1.2.4. By Distribution Channel
6.3.1.2.5. By Application
6.3.2. Canada Beta blockers Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Indications
6.3.2.2.3. By Drugs
6.3.2.2.4. By Distribution Channel
6.3.2.2.5. By Application
6.3.3. Mexico Beta blockers Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Indications
6.3.3.2.3. By Drugs
6.3.3.2.4. By Distribution Channel
6.3.3.2.5. By Application
7. Europe Beta blockers Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Indications
7.2.3. By Drugs
7.2.4. By Distribution Channel
7.2.5. By Application
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Beta blockers Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Indications
7.3.1.2.3. By Drugs
7.3.1.2.4. By Distribution Channel
7.3.1.2.5. By Application
7.3.2. France Beta blockers Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Indications
7.3.2.2.3. By Drugs
7.3.2.2.4. By Distribution Channel
7.3.2.2.5. By Application
7.3.3. United Kingdom Beta blockers Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Indications
7.3.3.2.3. By Drugs
7.3.3.2.4. By Distribution Channel
7.3.3.2.5. By Application
7.3.4. Italy Beta blockers Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Indications
7.3.4.2.3. By Drugs
7.3.4.2.4. By Distribution Channel
7.3.4.2.5. By Application
7.3.5. Spain Beta blockers Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Indications
7.3.5.2.3. By Drugs
7.3.5.2.4. By Distribution Channel
7.3.5.2.5. By Application
8. Asia Pacific Beta blockers Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Indications
8.2.3. By Drugs
8.2.4. By Distribution Channel
8.2.5. By Application
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Beta blockers Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Indications
8.3.1.2.3. By Drugs
8.3.1.2.4. By Distribution Channel
8.3.1.2.5. By Application
8.3.2. India Beta blockers Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Indications
8.3.2.2.3. By Drugs
8.3.2.2.4. By Distribution Channel
8.3.2.2.5. By Application
8.3.3. Japan Beta blockers Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Indications
8.3.3.2.3. By Drugs
8.3.3.2.4. By Distribution Channel
8.3.3.2.5. By Application
8.3.4. South Korea Beta blockers Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Indications
8.3.4.2.3. By Drugs
8.3.4.2.4. By Distribution Channel
8.3.4.2.5. By Application
8.3.5. Australia Beta blockers Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Indications
8.3.5.2.3. By Drugs
8.3.5.2.4. By Distribution Channel
8.3.5.2.5. By Application
9. Middle East & Africa Beta blockers Market Outlook
